Ballicules.com

Modafinil

PROVIGIL

What it isDopamine reuptake inhibitor and wake-promoting agent; narcolepsy, OSA-related sleepiness and shift-work disorder.

Why this oneIt promotes wakefulness with less sympathetic activation and lower abuse potential than amphetamine.

What limits itIt induces CYP3A4 enough to fail oral contraceptives, so alternative contraception is essential. Serious rash including SJS can occur.

FDA-approved for

Off-label

FDA label

FDA dosingPopulationStartTargetMax
NarcolepsyAdult200 mg QAM400 mg QD (no consistent added benefit)
Obstructive sleep apneaAdult200 mg QAM400 mg QD (no consistent added benefit)
Shift work disorderAdult200 mg QD, ~1 h before shift

Renal Undefined

Hepatic Reduce to one-half the recommended dose in severe hepatic impairment.

Instructions

Cautions

Adverse reactions

Pregnancy May cause fetal harm based on animal data; intrauterine growth restriction and spontaneous abortion reported.

Lactation Unknown whether excreted in human milk; exercise caution.

NO BOXED WARNINGS

Principal riskIt induces CYP3A4 enough to fail oral contraceptives

Cost, est. cash$5–$150/month

Generic entry2012

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4
Overdose danger2 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryC

Defining liabilitySerious rash, psychiatric activation and CYP-mediated interactions; misuse potential is present.

Mechanism of action: Modafinil ballicule

Modafinil ballicule: receptor binding, kinetics and half-life diagram

Open Modafinil in the interactive console ↗

Memory aids: mascots and interaction avatars

Modafinil PROVIGIL mascot mnemonic cartoon
“Moe daffodil is Pro-vigilant”
Modafinil CYP2C19 inhibitor avatar
CYP2C19 inhibitor (weak)
Modafinil CYP3A4 inducer avatar
CYP3A4 inducer (moderate)

Open Modafinil in the interactive console ↗